Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON29314
NL-OMON29314
Recruiting
Not Applicable

Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0.

AZM0 sites66 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIntestinal microbiota, microbiome, Colorectal cancer treatment, chemotoxicity, responsIntestinale microbiota, microbioom, colorectaal carcinoom behandeling, chemotoxiciteit, respons

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Intestinal microbiota, microbiome, Colorectal cancer treatment, chemotoxicity, responsIntestinale microbiota, microbioom, colorectaal carcinoom behandeling, chemotoxiciteit, respons
Sponsor
AZM
Enrollment
66
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Aarnoutse, R., de Vos-Geelen, J. M. P. G. M., Penders, J., Boerma, E. G., Warmerdam, F. A. R. M., Goorts, B., Olde Damink, S. W. M., Soons, Z., Rensen, S. S. M., and Smidt, M. L. (2017) Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0, International Journal of Colorectal Disease, 1-8.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
AZM

Eligibility Criteria

Inclusion Criteria

  • •Patients diagnosed with metastatic and/or irresectable CRC who will be treated with oral capecitabine (with or without intravenous bevacizumab) or oral trifluridine/tipiracil (TAS\-102\).
  • •Aged 18 years or older.

Exclusion Criteria

  • •Proven Microsatellite instability (MSI).
  • •Has not received any prior systemic therapy for the treatment of CRC during the previous 4 weeks prior to start of the current line of capecitabine or TAS\-102\.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of MetforminHuman Microbiome
NCT03809260Seoul National University Hospital20
Not yet recruiting
Phase 1
Study on the intestinal microflora characteristics and TCM syndromes of patients with hepatocellular carcinoma complicated with intestinal dysfunctioPrimary hepatic carcinoma
ITMCTR2200005950Changhai Hospital
Completed
Not Applicable
Intestinal microbiota analysis and dietary survey research for healthy subjects in middle ageHealthy adults
JPRN-UMIN000050561Sapporo University of Health Sciences150
Recruiting
Not Applicable
Characteristics of Intestinal Microbiome Following Pancreatic SurgeryPancreatic CancerMicrobiotaPancreatoduodenectomy
NCT06319755Royal Prince Alfred Hospital, Sydney, Australia20
Recruiting
Not Applicable
Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal CancerColorectal Neoplasms Malignant
NCT06714903The First Hospital of Jilin University50